Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 13/20 | 1.00 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 3/20 | 0.50 |
| ▸ | FLT1 | P17948 | 3/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.50 |
| ▸ | RET | P07949 | 2/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | KIF5B | P33176 | 1/20 | 0.49 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.48 |
| ▸ | FLT4 | P35916 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15665164 | 0.86 | KIT (1.00) | KITENPP1KDRFLT1FGFR1 | |
| SCHEMBL15663887 | 0.86 | KIT (1.00) | KIT | |
| SCHEMBL15665157 | 0.85 | KIT (1.00) | KITENPP1KDRFLT1FGFR1 | |
| SCHEMBL6182448 | 0.81 | KIT (0.78) | KITENPP1KDRFLT1FGFR1 | |
| SCHEMBL15665140 | 0.78 | KIT (1.00) | KIT | |
| SCHEMBL15516134 | 0.77 | KIT (1.00) | KITENPP1KDRFLT1FGFR1 | |
| SCHEMBL20782677 | 0.77 | ENPP1 (0.68) | KITENPP1 | |
| SCHEMBL22407456 | 0.76 | KIT (0.61) | KITENPP1KDRFLT1FGFR1 | |
| SCHEMBL30009847 | 0.76 | KIT (0.66) | KITKDRFLT1FGFR1RET | |
| SCHEMBL22407570 | 0.74 | ENPP1 (0.63) | KITENPP1RETLRRK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2892534-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-10227357-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-10227357-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20140128390-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | disclosed |
| US-20140128390-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | disclosed |
| US-20140128390-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227357-B2 | Compounds and methods for kinase modulation, and indications therefor | KIT, PRKCH, PRKACA | KIT 1/4885ENPP1 2173/4885KDR 151/4885 |
| US-20140128390-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, PRKCH, PRKACA | KIT 1/4885ENPP1 2173/4885KDR 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.